Overall, our results suggest that IFN-based treatments for COVID-19 face therapeutic challenges due to ZBP1-mediated inflammatory cell death that contributes to cytokine storm, tissue damage and ultimately lethality. The gene discussed is IFNA1; the disease is COVID-19.